88 results on '"Zielinski C"'
Search Results
2. ESMO Open: from Cancer Horizons to Science for Optimal Cancer Care—a tale stretching over 8 years
3. COP27 Climate Change Conference: urgent action needed for Africa and the world
4. Introducing pro and con discussions in ESMO Open—Cancer Horizons
5. ESMO Clinical Practice Guidelines: adapting and adopting new approaches for development, implementation and audit
6. 229MO Overall survival (OS) of palbociclib (P) plus endocrine therapy (ET) versus capecitabine (CAP) in hormone-receptor+/HER2- metastatic breast cancer (MBC) that progressed on aromatase inhibitors (AIs): Final results of the PEARL study
7. 415P Comparison of cetuximab every 2 weeks versus standard once-weekly administration for the first-line treatment of RAS wild-type metastatic colorectal cancer among patients with left- and right-sided primary tumor location
8. P-52 Overall survival with cetuximab every 2 weeks vs standard once-weekly administration schedule for first-line treatment of RAS wild-type metastatic colorectal cancer in patients with left- and right-sided primary tumor location
9. Professor Gouri Shankar Bhattacharyya
10. Biases in study design, implementation, and data analysis that distort the appraisal of clinical benefit and ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) scoring
11. Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant metastatic breast cancer: a phase III randomised controlled trial—PEARL
12. 143P Quality of life (QoL) with palbociclib (PAL) plus endocrine therapy (ET) versus (vs) capecitabine (CAP) in luminal metastatic breast cancer (MBC) patients (pts) in the PEARL study
13. Reduced seroprevalence against vaccine preventable diseases (VPDs) in adult patients with cancer: necessity of routine vaccination as part of the therapeutic concept
14. Characterization of MHC class II-restricted T-cell receptors for T-cell therapy of HBV infection
15. P2.15-03 Availability and Reimbursement of Diagnostic Testing and Novel Anti-Cancer Drugs for NSCLC in CEE: Results of a CECOG Survey
16. P2.12-04 Liposomal Irinotecan vs Topotecan in Patients with Small Cell Lung Cancer Who Have Progressed On/After Platinum-Based Therapy
17. Reply to the letter to the editor ‘ESMO-MCBS v1.1: statistical and patient relevant shortcomings’ by Emprechtinger et al.
18. Citrullinated histone H3, a biomarker of neutrophil extracellular trap formation, predicts the risk of venous thromboembolism in cancer patients
19. Reply to the letter to the editor ‘Re-aligning the ASCO and ESMO clinical benefit frameworks or modern cancer therapies’
20. Reply to the letter to the editor ‘Toxicity adjustment in the ESMO-MCBS: a Gestalt approach?’ by Del Paggio
21. Correcetions to “A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS)”
22. 300 Tonicity signals drive immunoparalysis and anti-inflammatory Th17 cell properties
23. ESMO-Magnitude of Clinical Benefit Scale version 1.1
24. Reply to the letter to the editor ‘Addressing the quality of the ESMO-MCBS’ by Del Paggio
25. MONDTI: Molecular characterisation platform for identifying actionable mutations in advanced or metastatic cancers
26. Final results of the TANIA randomised phase III trial of bevacizumab after progression on first-line bevacizumab therapy for HER2-negative locally recurrent/metastatic breast cancer
27. Reply to the letter to the editor ‘Utilisation of the ESMO-MCBS in practice of HTA’ by Wild et al.
28. Decreased body mass index (BMI) associates with impaired survival from diagnosis of brain metastases in lung cancer patients: analysis of 624 patients
29. Functional role of 4F2hc in pancreatic ductal adenocarcinoma
30. Exploratory analyses of candidate predictive and prognostic tissue biomarkers (BMs) in the open-label randomised phase III TANIA trial of bevacizumab (BEV) in HER2-negative locally recurrent/metastatic breast cancer (LR/mBC)
31. Temporal muscle thickness (TMT) is an independent prognostic parameter in patients with newly diagnosed brain metastases (BM) of breast cancer (BC)
32. 304 Tonicity signals drive and anti-inflammatory Th17 cell properties
33. PO-01 - Congestive heart failure is an independent risk factor for venous thromboembolism and mortality in cancer patients
34. Longitudinal analysis of hemostasis biomarkers in cancer patients during antitumor treatment
35. ESMO - Magnitude of Clinical Benefit Scale V.1.0 questions and answers
36. Reply to the letter to the editor ‘The ESMO Magnitude of Clinical Benefit Scaling Tool: from theory to practice’ by Hartmann and the letter ‘Comment on ESMO Magnitude of Clinical Benefit Scale’ by Muhonen et al.
37. 2926 Tumor-infiltrating lymphocytes (TILs) and PDL1 expression in lung cancer brain metastases
38. A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS)
39. P-177 Phase II trial of capecitabine + nab-paclitaxel in patients with metastatic pancreatic adenocarcinoma
40. Estimating risk of venous thromboembolism in patients with cancer in the presence of competing mortality
41. Factor V Leiden mutation increases the risk for venous thromboembolism in cancer patients – results from the Vienna Cancer And Thrombosis Study (CATS)
42. Delivering precision medicine in oncology today and in future—the promise and challenges of personalised cancer medicine: a position paper by the European Society for Medical Oncology (ESMO)
43. Activity of T-Dm1 in Her2-Positive Breast Cancer Brain Metastases
44. Phase III Study of Palbociclib in Combination with Exemestane Vs. Capecitabine, in Hormonal Receptor (Hr) Positive/Her2 Negative Metastatic Breast Cancer (Mbc) Patients with Resistance to Non-Steroidal Aromatase Inhibitors (Nsai): Pearl Study (Geicam/2013-02_Cecog/Bc.1.3.006)
45. Efficacy and Safety in Tania, a Randomised Phase III Trial of Continued or Reintroduced Bevacizumab (Bev) After 1St-Line Bev for Her2-Negative Locally Recurrent/Metastatic Breast Cancer (Lr/Mbc)
46. Tumor-Infiltrating Lymphocytes (Tils) and Pd-L1 Expression in Non- Small Cell Lung Cancer Brain Metastases (Bm) and Matched Primary Tumors (Pt)
47. Integrin Beta-3 Genetic Variants Predict the Risk of Thrombo-Embolic Events in Patients with Colorectal Cancer
48. Presence of varicose veins in cancer patients increases the risk for occurrence of venous thromboembolism
49. Rationale for targeting the immune system through checkpoint molecule blockade in the treatment of non-small-cell lung cancer
50. Safety results from a phase III study (TURANDOT trial by CECOG) of first-line bevacizumab in combination with capecitabine or paclitaxel for HER-2-negative locally recurrent or metastatic breast cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.